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Abstract
Context: Immune-checkpoint inhibitors (ICI) have shown significant benefits for overall survival across various
cancer types. Patient-reported outcomes (PROs) are assessed in clinical trials as a measure of efficacy. However, it
remains unclear to what extent current PRO instruments capture symptoms specific to ICI toxicities. We conducted
a systematic review to identify the use and content validity of PRO instruments in ICI clinical trials in oncology.
Methods: Literature was retrieved from PubMed, Embase, PsycINFO, Medline and CINAHL databases. Articles
presenting ICI clinical trials’ PRO results, clinical trial study protocols, and conference abstracts stating the use of
PRO measures were assessed. We evaluated the validity of identified instruments by comparing their symptom-
related content with the adverse events reported in each ICI clinical trial.
Results: From database inception until January 2020, we identified 191 ICI clinical trials stating the use of PRO measures of
which 26 published PRO results. The cancer-specific EORTC QLQ-C30 and the generic EQ-5D questionnaires were the most
widely used instruments, often in combination with disease-specific PROs. Instruments used to report PRO symptom-related
toxicities covered 45% of the most frequently reported AEs, whereas 23% of AEs were partially covered and 29% were not
covered at all. Of non-covered AEs, 59% referred to the dermatologic system. Partially covered AEs related to endocrine and
specific types of pain.
Conclusion: Despite the high frequency of symptom-related toxicities related to ICI, these events are only partially covered
(or not addressed) by current PRO instruments, even when combined. Further research is needed to develop new strategies
to tailor PRO instruments to specific ICI toxicities.
Keywords: Adverse events, Clinical trial, Immune-checkpoint inhibitors, Oncology, Patient-reported outcomes, Symptoms
Introduction
Immune-checkpoint inhibitors (ICIs) have shown signifi-
cant clinical benefit by improving treatment response
and survival rates for different cancer patient popula-
tions [1]. ICIs are associated with specific toxicities
related to inflammatory or autoimmune responses -
known as immune-related adverse events (irAEs) that
affect different organs and systems [2]. These irAEs re-
sult from broad and unspecific immune over-activation
[3]. In most cases, toxicities are reversible with cortico-
steroid or additional immunosuppressant treatment but
some rare and potentially life-threatening irAEs have
been reported [3]. Early recognition of irAEs and timely
management is essential to reduce morbidity and mor-
tality [4].
In clinical trials (CTs), the Common Terminology Cri-
teria for Adverse Events (CTCAE) is the most widely
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used method to report toxicities [5]. Of these, 10% focus
on symptomatic adverse events (AEs) amenable to pa-
tient self-report [6]. Thus, clinicians are often required
to evaluate subjective patient experiences – resulting in
potential underreporting of AEs [7, 8].
Patient-reported outcomes (PROs) are defined as “any
report of the status of a patient’s health condition that
comes directly from the patient, without interpretation of
the patient’s response by a clinician or anyone else” [9].
Several studies demonstrate that compared to clinician re-
port, PROs are more concordant with patient overall
health status and result in earlier detection of symptom
occurrence and severity [10, 11]. Thus, patient-reported
symptom assessment that incorporates items relevant to
ICIs may facilitate early AE detection and may provide
complementary data to support decision-making.
The overall aim of the study was to identify and
categorize the types and combination of PRO instru-
ments used in CTs involving cancer patients receiving
ICI therapy (ICI-CTs), and to assess their frequency of
use. To further examine the content validity of the PRO
instruments, we identified and compared the most fre-




This systematic review was conducted according to the
Preferred Reporting Items for Systematic Reviews and
Meta-Analysis (PRISMA) statement [12] and the proto-
col was prospectively registered with PROSPERO (regis-
tration number: CRD42018090912). A literature search
was performed in PubMed, Embase, PsycINFO, Medline
and CINAHL databases using search terms adapted to
the respective database. We used broad parameters
employing controlled vocabulary (MeSH/Emtree pre-
ferred and related concepts) as well as specific keywords
related to three constructs: (1) ICI terms (e.g. FDA-
approved ICI), (2) PRO terms and (3) oncology and im-
munotherapy terms (Table S1 in the Supplementary In-
formation). To ensure a comprehensive search strategy,
we used the CT identification number from selected
conference abstracts and CT study protocols to find
additional CTs with published PRO results. The search
was conducted from database inception to June 26, 2017
and updated on January 22, 2020. Articles written in
English, French, Spanish, and German were included.
Selection criteria
Four pairs of reviewers (SCL, SR, LM, DBL, ME, NK,
AC, AA) screened titles and abstracts following a prede-
fined list of inclusion/exclusion criteria (Table S2). A
Cohen’s kappa test was performed in order to ensure
consistency between reviewers (κ = 0.81). Full texts of
publications and conference abstracts were obtained and
reviewed independently by two pairs of reviewers (SCL,
SR, KR, LM) to identify articles for final analysis. Dis-
agreements were resolved by discussion to reach
consensus.
Types of publications included
Three types of publications were included (Fig. 1). Full-
text articles with PRO results served to evaluate the
reporting of PRO in ICI-CTs. CT study protocols and
conference abstracts were used to assess the use and
combination of PRO instruments in ICI-CTs and to
identify additional full-text articles reporting on PRO re-
sults in ICI-CTs.
Data extraction
Reviewers (SR, LM, KR, DFL) completed a structured,
online form using Distiller SR, to extract data from each
full-text article including study and ICI-CT characteris-
tics, analysis, results, study conclusions, and information
about the PRO instruments used in the study (Table S3).
Second reviewers (SCL and DS) verified the extracted
data. For CT study protocols and conference abstracts,
the following data were extracted: first author, publica-
tion year, study characteristics (name of the clinical
trial/study, CT identifier, start year, cancer type, and
number of participants), PRO endpoints, and name of
the PRO instrument(s). Collected information was com-
pleted and verified across sources: clinicaltrials.gov/
EudraCT, published CT protocol (when available), and
primary CT publication (Table S4).
Categorization, combination and frequency of use of PRO
instruments
Identified PRO instruments for all ICI-CTs were
grouped into categories based on the focus of the meas-
ure (e.g. generic, cancer-specific, disease/tumor-specific,
symptom-specific, item bank/single items, or other) and
their frequency of use and combination were subse-
quently analyzed. The Cochrane checklist for describing
and assessing PROs in CTs [13] was applied to the full-
text articles presenting PRO results to assess measure-
ment properties of the PRO instruments and PROs
reporting (Table S5).
Comparison of PRO symptom content and most frequent
reported AEs
We examined the content validity of PRO instruments
used in the full-text articles reporting PRO results by
comparing the extent to which the symptom-related
content of identified PRO instruments (Table S7)
aligned with the ten most frequent AEs reported in their
respective CT study publication (Tables S8). A panel of
experts including oncologists, advanced practice
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oncology nurses, and oncology nursing researchers
reviewed and, through consensus, agreed on the differ-
entiation of complex AEs into multi-symptoms that can
be reported by patients (Table S9). AEs were considered
‘covered’ when the item matched all corresponding
symptoms contained in the PRO instrument. Conversely,
items were considered ‘not covered’ when PRO instru-
ments did not include the corresponding symptom.
Multi-symptom AEs were considered ‘partially covered’
when at least two of the symptoms pre-defined (Table
S9) were contained in the PRO instrument(s). Coverage
of the most frequently reported AEs (for each ICI-CT
arm) were calculated and reported as a percentage.
Results
The search yielded 5295 records. After removing dupli-
cates and screening titles and abstracts, 398 publications
remained. Subsequent full-text assessment identified 27
articles reporting ICI-CTs PRO results, 319 conference
abstracts, and 9 published CT study protocols. An
Fig. 1 PRISMA chart mapping the number of records identified, selected, and included for final analysis. Twenty-eight full-text articles reporting
PRO results referring to 26 ICI-CTs, 9 study protocols, and 319 conference abstracts stating the use of PRO measures in ICI-CTs, were retained for
data extraction
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additional article reporting PRO results was identified
through conference abstracts and was included in the
final analysis (total articles n = 28) (Fig. 1). Detailed
review of articles, CT study protocols, and conference
abstracts identified 191 ICI-CTs. We found information
on PRO instruments for 156 of these ICI-CTs (Figure S1
and Table S4).
Categorization, combination and frequency of use of PRO
instruments in ICI-CTs
The number, categorization, and combination of PRO
instruments for each of the 156 ICI-CTs is shown in Fig. 2
and supplementary Table S4. Data review and analysis of
the 156 ICI-CTs showed an increase over the years of the
number of ICI-CTs stating the use or measurement of
PROs in publications or conference abstracts (Fig. 2a).
The peak was reached in 2015, with 32 ICI-CTs, followed
by a plateau in the consecutive years. In the same period
of time an increase of ICI-CTs can be observed (Figure
S1).
Of the 156 ICI-CTs, 35 used one instrument, 68 used
two instruments, 41 used three instruments, and 12 used
four or five instruments (Fig. 2c and Table S4). Among
the 68 ICI-CTs using two instruments, 16 paired generic
with cancer-specific, 10 paired generic with disease/
tumor-specific, 39 paired cancer-specific and disease/
tumor-specific, and the rest (n = 3) combined a disease/
tumor or cancer-specific with a symptom-specific ques-
tionnaire (n = 1), a treatment-specific (n = 1), or selected
items (n = 1). In studies using three instruments, combin-
ing generic, cancer-specific, and disease-specific question-
naires was the most commonly used approach (n = 30/41).
The other 11 ICI-CTs combined generic or cancer-
specific instruments with disease-specific and symptoms
or single item from item-libraries. Of the 12 ICI-CTs that
used four or five instruments, most of them combined
generic, cancer-specific and disease/tumor-specific
with either symptom questionnaires or single items se-
lected from item libraries such as the Patient Reported Out-
comes Measurement Information System (PROMIS), the
PRO version of the CTCAE (PRO-CTCAE), or the Euro-
pean Organisation for Research and treatment of Cancer
(EORTC) (Fig. 2c).
The cancer-specific EORTC Quality of Life Question-
naire Core 30 (EORTC QLQ-C30) was the most widely
used PRO instrument (112/156, 72%), followed by the
generic health EuroQol 5 Dimension Scale (EQ-5D)
(72/156, 46%) (Fig. 2b).
Focusing on the evolution of the use of PROs
over time, we observe two main periods. Between 2004
Fig. 2 Frequency of use and combination of PRO instruments in ICI-CTs (n = 156). a Number of PRO instruments divided into categories and
start year of the ICI-CTs. Green: general health status; Blue: cancer-specific; Red: disease/tumor-specific; Yellow: symptom-specific; Dark blue: items
libraries/single items; Purple: other (e.g. treatment-specific). b Absolute number of instruments across all ICI-CTs divided per category. The table
shows the different instruments per category. c Number and combination of PRO instruments per ICI-CT per year of start of the trial. For FACT
questionnaires that include core domains of the FACT-G, both cancer-specific and disease specific have been depicted (see Table S4 for more
detail). For ICI-CTs colored in light grey PRO results have been published (n = 26)
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and 2013, few studies used single instruments with the
majority (8/15) of studies using two instruments. Be-
tween 2014 and 2019 (n = 141), we observe a higher vari-
ability in the number of instruments used (Fig. 2a).
Articles reporting on PRO results
From the 28 full-text articles reporting PRO results, one
discussed associations between biomarkers and PRO
results, 18 reported PRO results alone, and seven presented
safety and efficacy data from the main ICI-CT together
with PRO results. For two of the latter, additional full-text
manuscripts on PRO results alone were published. Thus,
the 28 publications referred to 26 individual ICI-CTs on
lung carcinoma (n = 11) [14–24], melanoma (n = 6) [25–
30], renal cell carcinoma (n = 3) [31–33], urothelial carcin-
oma (n = 2) [34, 35], Hodgkin’s lymphoma (n = 1) [36, 37],
head and neck carcinoma (n = 1) [38, 39], Merkel cell car-
cinoma (n = 1) [40], and cervical and vaginal carcinoma
(n = 1) [41] (Table S5). With regard to measured PRO con-
cepts, all publications reported on health-related quality of
life (HRQoL) or global health status (GHS) as assessed by
the cancer-specific EORTC QLQ-C30 (17/26) and/or the
generic EQ-5D (15/26). Eleven publications additionally in-
cluded the measure of disease-related symptoms, and an-
other four added a function assessment. In general, the
selection of the PRO instrument(s) was justified based on
previous use and validation in similar patient populations -
either general cancer patients or disease-specific popula-
tions (Table S5). Only one publication [40] re-validated
the instrument in the study population and the psycho-
metric results have been published elsewhere [42].
Overall, most of the publications reported differences
between groups in terms of “clinically meaningful
deterioration”, “clinically meaningful improvement”, “clin-
ically relevant”, “stable”, “minimal change”, “statistically
significant”, or “significant difference” (Table S5). The
primary reasons for attrition and missing PRO data were
disease progression and AEs (15/26) (Table S6).
Content validity of PRO instruments
The use of the Cochrane checklist (Table S5) revealed a
lack of coverage of common ICI-related AEs. We
extracted the symptom-related content of each PRO
instrument used in each of the 26 ICI-CTs identified
(Table S7), followed by the extraction of the AEs reported
in the main CT publication (Table S8). We then charted
the ten most frequent AEs (any grade) reported in the
respective ICI-CTs denoting which AEs were covered by
PRO instruments employed in the corresponding study
(Fig. 3). In total, almost half of the AEs (142/299, 47%)
were covered by PRO instrument(s) employed in the
ICI-CTs, even when used in combination. Nearly a
third of AEs reported in ICI-CTs were not covered by the
PRO instrument(s) (86/299, 29%). Among ‘not covered’
AEs, 51/86 (59%) were dermatologic in nature (e.g. rash,
pruritus, vitiligo, dry skin). Further, multi-symptom AEs
were partially covered in 71/299 (24%) of which 34%
(24/71) related to a specific type of pain (e.g. headache, arth-
ralgia, myalgia) and 28% (20/71) were endocrine-related (e.g.
hypothyroidism, hyperthyroidism, hypophysitis).
Discussion
This systematic review examines the use of PRO
instruments in clinical trials of FDA-approved ICI (up to
January 2020). Our analysis reveals the cancer-specific
EORTC QLQ-C30 and the generic EQ-5D questionnaires
are the most widely used PRO instruments (72% and 46%,
respectively) - either alone or in combination with
disease-specific instruments. Although we observed an in-
crease in the stated use of PRO measurements in ICI-CTs,
reaching a peak in 2015, this should be seen in the global
context of ICI development and the increase in ICI-CTs
over the years. HRQoL or QoL are the most frequent
measured concepts and only one third of the articles
included additionally disease-specific symptom measures.
Furthermore, our results indicate that the used PRO
instruments did not include items specifically relating to
ICI treatment-related symptoms. These results raise
important concerns about the comprehensiveness of
current instruments and the measurement of relevant
PROs in the context of ICI-CTs. Similar conclusions have
been drawn in other recently reported studies of PROs in
ICI-CTs [43, 44]. However, the rigorous approach used in
our review offers new, more detailed, and compelling
insights about the use and content validity of PRO instru-
ments in ICI-CTs. First, we provide a more comprehen-
sive assessment of the aggregate content of PRO
instruments in relation to frequent AEs by identifying and
categorizing all the PRO instruments used in each ICI-CT
(Fig. 3). In contrast, Hall et al. [44] only examined PRO in-
struments related to symptoms contained in the EORTC
questionnaire. Secondly, our study examined the full
spectrum of AEs reported in each ICI-CT (Fig. 3) as op-
posed to King-Kallimanis et al., who limited their examin-
ation to eight pre-selected symptoms for anti-PD-1/PD-L1
agents [43].
The use of PROs in CTs has grown in the last decade
and PROs are recommended as important endpoints for
trials [9, 45]. However, the availability of validated ques-
tionnaires and use of the most suitable instruments
remains a challenge urging caution when interpreting
HRQoL data in ICI-CTs [46–48]. A recent review of stud-
ies that led to the approval of ICIs identified several meth-
odological problems with PRO measurement. Specifically,
general HRQoL measures might lack sensitivity to provide
a comprehensive assessment of the impact that ICI
therapies have on patients [49]. For instance, some studies
report no differences in HRQoL of ICI-treated patients
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despite relatively frequent grade 3–4 toxicity. Broadly, ICI-
CTs results suggest a stable or overall increased HRQoL
yet specific ICI treatment-related symptoms and AEs are
not adequately assessed by existing PRO tools. In our study,
we identified that dermatologic, endocrine, and specific
types of pain are among the most reported ICI-related
problems regardless of cancer type/diagnosis. Despite the
frequency of such events, these AEs are only partially cov-
ered if at all by currently applied PRO instruments.
Studies included in this analysis often employed a
combination of different PRO instruments (e.g. generic
and cancer-specific, cancer-specific with disease-specific
and/or symptom-specific questionnaires). The advantage
of generic instruments is their broad applicability for
evaluating general aspects of HRQoL independent of the
specific diagnosis. However, generic instruments tend to
lack responsiveness for detecting deterioration in specific
health contexts. Disease- or symptom-specific instruments
may be more acceptable and responsive to detecting
changes but have limited generalizability for identifying
unanticipated events across different populations [13]. In
the present review, studies employed PRO instruments
based on the intended measure (e.g. to detect changes in
HRQoL, GHS, specific disease-related symptoms). Closely
examining ICI-related toxicities revealed a unique profile -
independent of cancer diagnosis [50–52]. This observation
challenges the practice of choosing PRO instruments based
on the population rather than treatment type. In other
words, both cancer-specific tools and generic HRQoL ques-
tionnaires designed for traditional chemotherapies may not
capture symptoms and toxicities specific to ICI therapies.
Following this line of thought, Kluetz and colleagues have
suggested the individual measurement of symptomatic ad-
verse events, physical function, and disease-related symp-
toms. These three concepts are highly relevant to HRQoL
and may better reflect the therapy’s effect on the patient
and the patient’s disease [53]. An alternative approach to
the traditional static instruments is the use of item libraries
or computerized adaptive testing with content and
symptom-items adapted for ICI treatments such as the
Fig. 3 Comparison of PRO instruments’ symptom-related content and AEs reported in ICI-CTs with published PRO results (n = 26). The
most frequently reported AEs (any grade) are shown for the 26 ICI-CTs identified. AE frequency (most common to least common) is
depicted from left to right respectively. Symptom-related content from each PRO instrument was compared to the AEs in the
corresponding trial arm. The PRO instruments used in each ICI-CT is shown. For a detailed PRO instrument content, see Table S8. Green:
AEs covered; Yellow: AEs partially covered; Light yellow: AEs partially covered related to specific types of pain; Red: AEs not covered.
Laboratory tests results (grey) were not included in calculations. “Asthenia” was considered covered by “fatigue” following the National
Cancer Institute toxicity grading scale version 3 that included asthenia, lethargy, and malaise under the umbrella of “fatigue”. (1) “Fatigue”
was considered partially covered because the term included in the FACT-G was “lack of energy”; (2) While the study protocol announced
the use of SF-36, EORTC QLQ-C30, FACIT-Fatigue, and SDS questionnaires, only results from the EORTC QLQ-C30 were reported in the full-
text publication. “Cough” would be covered by the SDS instrument; (3) “Chills” was partially covered as related to “fever”, included in the
FACT-G; (4) “Dec. appetite” was considered as partially covered by the term “good appetite” in the FKSI-19. Ipi, Ipilimumab; Niv,
Nivolumab; Pem, Pembrolizumab; Ate, Atezolizumab; Dur, Durvalumab; Inc., increased; Dec, decreased
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National Cancer Institute PRO-CTCAE, PROMIS or the
EORTC item library [6, 54–56]. Recently, efforts have been
undertaken to develop such ICI specific modules [57].
Our study highlights the general underreporting of PRO
results. Of 3231 ICI-CTs registered in the period between
2004 and 2019, only 191 (6%) had a published statement
(study protocol, conference abstract) about the measure-
ment of PROs, of which only 26 had a full-text article on
PRO results. This finding aligns with the results from a
recent systematic evaluation of PROs in cancer trials by
Kyte et al. [58]. Importantly, PROs inform and facilitate
treatment decision-making in clinical practice. As such,
systematic PRO collection, analysis and reporting are
highly relevant and should be considered a priority. This
delay in PRO reporting is at odds with recommendations
from both the European and American oncology societies
(ESMO and ASCO) to incorporate such measures in
clinical trials as read-outs for treatment benefit evaluation
[59, 60].
Conclusion
Our systematic review on the use of PROs in ICI-CTs
identifies variability in the use of instruments and gaps
in existing instruments for addressing symptomatic
toxicities that are ICI treatment-related. Further work is
needed to develop novel strategies that permit the more
comprehensive and systematic collection of PRO data
specific to ICI treatments to inform and support drug
labelling and clinical decision-making.
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